Aesgen, Inc.

L-glutamine formulation helps prevent, treat common chemotherapy side effect

Published in Aging and Elder Health Week, July 4th, 2004

Aesgen, Inc., a privately held, emerging pharmaceutical company, announced results from its pivotal Phase III trial that show Saforis (L-glutamine) for oral suspension significantly reduced the severity and duration of clinically significant oral mucositis in breast cancer patients receiving standard chemotherapy treatments.

These data reinforce earlier study results that show Saforis reduces the severity and duration of oral mucositis and the need for narcotic pain control in a range of cancer patients undergoing chemotherapy or radiation therapy.

The study was presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Aging and Elder Health Week

Source: Aging and Elder Health Week (2004-07-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry